In 2022, these five pharmaceutical stocks jumped 85 per cent; do you own these multibaggers?

The financial year 2021–22 saw another strong result from the Indian pharmaceutical companies.

The financial year 2021–22 saw another strong result from the Indian pharmaceutical companies. These five pharmaceutical businesses have virtually become multibagger ">Multi-baggers and produced significant returns despite the volatility. Let’s find out what are those:  

1. Jagsonpal Pharmaceuticals 

The company gained more than 85 per cent so far, in 2022. The company's stock is now trading at Rs 333 from Rs 179 at the beginning of the year. It is India's one of the top pharmaceutical companies. It has strong skills in manufacturing, marketing, and distribution. The corporation had announced an equity dividend of 5 per share with a 1.5 per cent yield for the fiscal year.  

2. Lactose India

By providing them with profits of more than 75 per cent, the company has made investors happy. The stock of the company is now trading at Rs 75 after opening the year at Rs 39. The business offers edible & medicinal-grade lactose, which is a component of drinks, dairy products, confections, and pharmaceutical goods.  

3. Syschem India  

In 2022, the company's share price soared 54 per cent. It is now trading at Rs 26 after opening the year at Rs 17. A publicly-traded firm called Syschem India Ltd (SIL) produces contract manufacturing, speciality chemicals, intermediates, and bulk pharmaceuticals.  

4. Parnax Labs

In 2022, the company has given out excellent returns of more than 57 per cent. It is currently trading at Rs 80 after opening the year at Rs 58. Founded in 1982, Parnax Labs is a Small-Cap business in the pharmaceutical industry. The financial sheet of the company reveals that it has started to produce positive cash flows from operating activities, which should gradually lower its debt.  

5. Zim Laboratories

The company's stock price surged 54 per cent so far, in 2022. Stock in the corporation is now trading at Rs 189 after beginning the year at Rs 118. By utilising its in-house technological know-how, manufacturing process expertise & unique knowledge, the company closes the technology gap.  

Investors must keep a watch on these equities for the upcoming sessions.